Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A new analysis of the ANGEL-TNK trial finds that giving intra-arterial tenecteplase after a successful thrombectomy significantly boosts stroke recovery — and the benefit holds up a full year later. Nearly 46% of treated patients achieved excellent functional status versus 28% with standard care. Importantly, there was no increase in long-term mortality.
A prespecified secondary analysis of the ANGEL-TNK trial reveals that administering intra-arterial tenecteplase following successful endovascular thrombectomy (EVT) leads to meaningfully better neurological outcomes — and those gains are still going strong 12 months later. The trial enrolled 255 adults in China with anterior circulation large vessel occlusion strokes who presented 4.5 to 24 hours after symptom onset and had not received prior IV thrombolysis.
Patients who received low-dose intra-arterial tenecteplase (up to 12.5 mg) after EVT were significantly more likely to achieve excellent functional status at one year compared to those on standard treatment alone — without any uptick in mortality, reinforcing the drug's long-term safety profile.
Why it matters: For stroke patients undergoing thrombectomy, the window for improving outcomes doesn't close at discharge. This study suggests that adding a low-dose clot-dissolving agent right after the procedure can translate into real, lasting functional gains — a potentially practice-changing finding for stroke care teams.
